Michael McElhaugh compensation by year
Arbutus Biopharma Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $109,658 |
| Bonus | $0 |
| Stock awards | $582,330 |
| Option awards | $1,855,495 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $1,030,667 |
| Total | $3,578,150 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 14, 2026, accession 0001140361-26-014623, and prior-year filings. Open the filing on EDGAR.
Change-in-control & termination
estimated payments Arbutus Biopharma discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $986,825 | — | — | $986,825 |
Per the Potential Payments Upon Termination or Change in Control table in Arbutus Biopharma Corp's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Arbutus Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael McElhaugh · this page | Former Interim President and Chief Executive Officer | $3,578,150 |
| Tuan Nguyen | Chief Financial Officer | $2,416,995 |
| David Hastings | Former Chief Financial Officer | $2,218,362 |
| Lindsay Androski | President and Chief Executive Officer | $1,369,013 |
The full Arbutus Biopharma compensation record
free company briefThis page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arbutus Biopharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat